March-in rights are the most misunderstood clause in federally funded research. They do not let the government take your patent, and they never have. What they permit is narrower and stranger: under specific conditions, a funding agency can require you to grant a license to a responsible applicant on reasonable terms, or grant that license itself if you refuse.
What the statute actually permits
Bayh-Dole gives the funding agency authority to march in when one of a short list of conditions is met. The remedy is compulsory licensing, not confiscation. You keep title. You keep the right to practice the invention. What you lose in a successful march-in proceeding is exclusivity, because someone else gets a license too — and the statute contemplates that license being on reasonable terms, meaning you would still be compensated. This is a meaningfully different outcome from losing the asset, and it is worth saying plainly to investors who have heard the scarier version. Note also that a separate, routine thing already exists and is often confused with march-in: the government's own paid-up license to practice the invention for its own purposes, which attaches automatically to every subject invention.
The conditions are narrow
The listed grounds are essentially: that the owner has not taken effective steps to achieve practical application of the invention within a reasonable time; that action is necessary to alleviate health or safety needs not reasonably satisfied; that action is necessary to meet requirements for public use specified by federal regulations and not reasonably satisfied; and that the US manufacturing preference has been breached without a waiver. The process is adversarial and slow — the agency investigates, you respond, and there are appeal rights before anything takes effect.
They have essentially never been exercised
Petitions have been filed, most visibly at NIH over drug pricing, and every one of them has been declined. No federal agency has ever completed a march-in and forced a license. That track record is the single most useful fact for a founder worried about this clause: the practical risk to a small company diligently commercializing its technology is very low. It is not zero — an authority that exists can be used, and the conditions do include failure to commercialize, which is a real if remote exposure for a company that shelves a funded invention. Investors doing IP diligence will ask; the honest answer is that it is a disclosed, well-understood, historically unexercised encumbrance, not a defect in title.
Why the debate is worth watching
Periodically, policymakers propose reading the conditions more broadly — most prominently the argument that an unreasonably high price for a federally funded product could itself trigger march-in. Draft frameworks along those lines have been circulated and contested, and the question is not settled. If you are commercializing a federally funded invention in a price-sensitive sector, this is worth following, not panicking about. It sits alongside the ownership rules, the terms of any license you grant, and the general tradeoff between non-dilutive funding and equity.
This is general information, not legal advice. Anything touching march-in belongs with counsel experienced in federal contracting.
Projects House helps companies turn federally funded research into products people actually buy. Start with the contact form.